tbuckley/cabot-search huggingface dataset:
Die Chirurgie: Eine zusammenfassende Darstellung der allgemeinen und der speziellen Chirurgie.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letter: Interim pay review.
Journal: BMJ (1975)

compromise already suggested by our negotiators), thus removing the objection that the payment would result in full-timers being paid for doing nothing.(4) Item-ofservice fees or an on-call allowance to be paid for any duties outside the nine-or 10-session basic commitment.( 5) The equivalent of the present merit awards to be distributed impartially to part-time as well as full-time consultan,ts.( 6) No fixed 9 a.m. to 5 p.m. "clocking on and off" regulations and no compulsion to take meals in hospital.
Correction
Authors: U Mukhtyar, V Munot, U Nag, W Mcl, T Naismith, C Nasah, Pauline Naylor, B Naylor, H Obi, J O'connor, S Oni-Orisan, Maria-Danuta Pandit, P Paszkowski, Adeline Paterson, Foo Patterson, D Pau, I Penny, A Peters, J Prakash, S Quilter, D Qureshi, G Rawling, Hala Sarkar, A Sarsam, F Sawhney, J Schokman, A Scrimgeour, A Sen, F Shah, Barbara Sharp, T Smith, S Spencer, G Steigrad, J Stirrat, T Sunna, Y Tadro8, P Tan, Kee Seng, Soon Teo, C Teoh, R Venning, P Ward, R Whiteley, Rosemary Williams, S Williams, A Wood, John Peel, Audrey Ward, John Peel; Vice-Presidents, J Stall- Worthy;, Mr Alment, Mr Gunn, Mr Haines, Mr Roberts, Mr Gill, ; Canada
Journal: BMJ (1968)
Toxic Potential of the Plasticizer Di(2-ethylhexyl) Phthalate in the Context of Its Disposition and Metabolism in Primates and Man
Authors: Carl C. Peck, Phillip W. Albro
Journal: Environmental Health Perspectives (1982)

Although human toxicity from exposure to the plasticizer di(2-ethylhexyl) phthalate (DEHP) is unknown, reports of animal toxicity from DEHP have stimulated extensive toxicological studies. In the absence of direct toxicity data, information on the disposition and metabolism of DEHP in primates and man may enhance our assessment of the toxic potential of DEHP in man. Studies of DEHP disposition and metabolism in the African Green monkey and man show that the compound is rapidly and extensively metabolized. It is excreted largely in the urine (greater than 90%) as conjugated (glucuronide) oxidation products of mono(2-ethylhexyl) phthalate; excretion in feces accounts for the other 10% of the administered DEHP. Plasma disappearance of parenterally administered DEHP is equally rapid so that by 24 hr following DEHP administration, plasma DEHP concentrations are virtually undetectable, while greater than 70% of the dose has been excreted in urine and stool. The transience of DEHP in primates and the extent to which it is metabolized and conjugated may play a role in the observed lack of toxicity.
Isoniazid chemoprophylaxis
Authors: S. Grzybowski
Journal: JAMA (1986)

The idea of isoniazid chemoprophylaxis was first conceived over 30 years ago by a group of workers in the Public Health Service led by the late Dr Carrol Palmer. A series of excellently conducted trials followed, directed by Drs Shirley Ferebee Wolpert and George Comstock, showing that isoniazid prophylaxis reduces morbidity from tuberculosis by some 50% to 80% in individuals who took the drug for a period of 12 months.<sup>1</sup> We realized at that time that in North America the stage had been reached where the majority (perhaps as many as 80%) of all the cases of active tuberculosis were arising as a result of remotely acquired infection in persons infected many years, often a number of decades, previously.<sup>2</sup>We estimated that if these previously infected tuberculin-positive individuals would take isoniazid for one year, we could reduce tuberculosis morbidity in North America by at least half. Sporadic attempts
Guidelines for interactions with pharmaceutical companies
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PWE-094 The Prevalence of Anaemia in Inflammatory Bowel Disease in Relation to Disease Activity, as Stratified by Faecal Calprotectin
Authors: M Muscat, N A Kennedy, J Chang, J Satsangi, I D Arnott, K Kingstone, C W Lees
Journal: Gut (2013)

<h3>Introduction</h3> The prevalence of anaemia in IBD varies significantly between published studies, ranging from 6–74%. However, underlying disease activity, a potential explanation for this variability, has not been accurately correlated with the frequency of anaemia to date. Faecal calprotectin (FC) is a surrogate marker of underlying mucosal inflammation. The objective of this study was to investigate the prevalence of anaemia and its correlation with disease activity in IBD, in a large cohort of patients with matched full blood count (FBC) and FC data. <h3>Methods</h3> Patients with confirmed IBD from the Edinburgh faecal calprotectin registry (EFCR) were identified. Where multiple FCs were available, the most recent result was taken as reference. Blood test results were obtained from the electronic record covering a period one month either side of the FC. The WHO criteria was used to define anaemia (Hb &lt; 130 g/L in men, &lt; 120 g/L in women). A FC value of ≥200 µg/g was used to indicate active disease. The cohort was subdivided into 4 groups: active and inactive Crohn’s disease (CD), active and inactive Ulcerative colitis (UC). <h3>Results</h3> 1226 patients (771 CD, F = 65%, 455 UC, F = 35%) with matched FC and FBC data were analysed. The median age was 44y (IQR 31–57), median disease duration 102 months (IQR 31–207). Overall, 314/1226 patients (25.6%) were anaemic, 185/314 (58.9%) of which were female. Anaemia was observed more frequently in patients with active as opposed to inactive CD (110/328 [33.5%] vs 65/443 [14.7%], p &lt; 0.0001). This pattern was also seen in patients with UC (129/293 [44%] vs 23/162 [14.2%], p &lt; 0.0001). The prevalence of anaemia in active UC was greater than in active CD (p = 0.014); however, this could be explained by the higher median FC in the UC cohort (900 vs. 618, p &lt; 0.0001). There was no statistically significant difference in age or Montreal location (L1 + L3 vs L2, p = 0.16) between the groups. ROC analysis of FC as a predictor of anaemia showed an AUC of 0.69 with a sensitivity and specificity of 0.73 and 0.57 respectively at a cut off of 200 µg/g. <h3>Conclusion</h3> In this cohort over 25% of patients with IBD were anaemic. There is a clear correlation between disease activity and anaemia in both CD and UC, but this is unrelated to disease distribution in CD. Anaemia in asymptomatic patients should alert clinicians to the possibility of subclinical active mucosal inflammation. These data and the ROC analysis provide further support for optimising disease treatment in IBD, targeting a FC level of &lt; 200 µg/g. <h3>Disclosure of Interest</h3> None Declared.
Clinical Features of Diphtheria in the Respiratory Tract
Authors: Robert A. Dobie
Journal: JAMA (1979)

Clinical features of 44 culture-confirmed cases of diphtheria involving the respiratory tract treated at the University of Washington and affiliated hospitals in Seattle over a five-year period were studied. Of 42 patients treated primarily in Seattle, five (11.9% died; nonfatal, toxin-induced complications occurred in seven (16.7%). Airway obstruction was the most common cause of death in this series. Diphtheritic membrane (especially in the larynx), dyspnea, and leukocytosis were dire prognostic signs. We urge indirect laryngoscopy in all cases showing membrane formation; tracheotomy should be considered when laryngeal membrane is present. Diphtheria should be suspected in any patient with pharyngitis who has been in contact with endemic areas, especially when pharyngeal membrane is present. (<i>JAMA</i>242:2197-2201, 1979)
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
Authors: J.B. Muhlestein, J.L. Anderson, E.H. Hammond, L. Zhao, S. Trehan, E.P. Schwobe, J.F. Carlquist
Journal: Journal of the American College of Cardiology (1998)
Childhood Influenza Vaccination Coverage—United States, 2004-05 Influenza Season
Journal: JAMA (2007)

Children aged <2 years are at increased risk for influenza-related hospitalizations, and children aged 24-59 months are more likely than older children to visit a clinic, hospital, or emergency department with influenza-associated illness. In 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged annual influenza vaccinations for children aged 6-23 months (and for household contacts of and out-of-home caregivers for children aged <2 years). For the 2004-05 influenza season, ACIP strengthened its encouragement to a full recommendation. For the upcoming 2006-07 influenza season, ACIP has further extended its recommendation to include all children aged 6-59 months (and their household contacts and out-of-home caregivers). Others recommended to receive influenza vaccination include children aged 6-18 years who have certain high-risk medical conditions, are on chronic aspirin therapy, or who are household contacts of persons at high risk for influenza complications. This report provides an assessment of influenza vaccination coverage among children aged 6-23 months during the 2004-05 influenza season. The findings demonstrate that vaccination coverage in that age group approximately doubled from the 2003-04 influenza season, with substantial variability among states and urban areas. However, the percentage of fully vaccinated children remained low, underscoring the need for increased measures to improve pediatric vaccination coverage and ongoing monitoring of coverage among young children and their close contacts.
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).
Authors: Christopher M. Booth, Janette L. Vardy, Sharlene Gill, Derek J. Jonker, Christopher J. O'Callaghan, Christine Friedenreich, Ralph M. Meyer, Michael Brundage, Rebecca Wong, Haryana M. Dhillon, Patti O'Brien, Emma Goddard, Neil Sun Chua, Sasha Lipichuk, Michael Susmoy Sanatani, Philip James Beale, Stephen Begbie, Stephen P. Ackland, Dongsheng Tu, Kerry S. Courneya
Journal: Journal of Clinical Oncology (2014)

TPS3663 Background: Observational studies indicate that physical activity (PA) is associated with colon-cancer specific survival. The National Cancer Institute of Canada Clinical Trial Group CO.21 (CHALLENGE) trial is designed to determine the effects of a structured physical activity (PA) intervention on disease-free survival in high-risk stage II or III colon cancer survivors who have completed adjuvant chemotherapy within the previous 2-6 months. Methods: Phase III randomized controlled trial. Target sample size of 962 patients is powered to detect a Hazard Ratio of 0.75 for disease-free survival (DFS). Trial participants are stratified by centre, disease stage, body mass index, and performance prior to randomization to a structured PA intervention or general health education materials. The PA intervention consists of a behavioural support program and supervised PA sessions delivered over a three-year period, beginning with regular face-to-face sessions and tapering to less frequent face-to-face or telephone sessions. The goal of the PA program is to increase weekly PA by 10 METhours/week. The PA program is delivered by physical activity consultants trained in exercise physiology and behavior change. Outcomes:The primary endpoint is DFS. Important secondary endpoints include multiple patient-reported outcomes (including those that address fatigue), objective physical functioning, biologic correlative markers (including assessment of the insulin pathway), and an economic analysis. Data is also being collected on motivational outcomes and behavior change that will inform program delivery. Current Enrollment:The study is open at 20 centers in Canada and 26 centers in Australia and will open in other countries in 2014. Accrual as of February 3, 2014 includes 311 registered and 262 randomized patients. Summary: Cancer survivors and cancer care professionals are interested in the potential role of PA to improve disease-free survival and quality of life. A randomized controlled trial is needed to provide compelling evidence to justify changes in health care policies and practice. Clinical trial information: NCT00819208.
MYCOTIC ANEURYSMS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Benign, Encapsulated Tumors in the Lateral Ventricles of the Brain: Diagnosis and Treatment
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doctors need an answer on the duty to prescribe
Journal: BMJ (1998)

Nut consumption may protect against heart diseaseAlthough nuts are high in fat, the fatty acids are mostly monosaturated or polyunsaturated, which have beneficial effects on blood lipids.In a large prospective study of women, Hu et al (p 1341) found an inverse association between nut consumption and incidence of coronary heart disease.Women who frequently consumed nuts (>5 times per week) had a significantly lower risk of non-fatal myocardial infarction and fatal coronary disease after accounting for age, smoking, and other known coronary risk factors than women who rarely (never or less than once a month) ate nuts.
The role of angiotensin system inhibitors (ASIs) in the outcome of sunitinib treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC).
Authors: J. J. Kim, P. Huang, M. A. Eisenberger, R. Pili, E. S. Antonarakis, H. J. Hammers, M. A. Carducci, D. Keizman
Journal: Journal of Clinical Oncology (2011)

e15008 Background: The VEGFR inhibitor sunitinib is a standard tx for mRCC. ASIs include angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). ASIs are used in the tx of hypertension, kidney disease, and heart failure. Pre-clinical and clinical studies in several cancer types have shown that they may inhibit tumor growth. Their effect on the outcome of sunitinib in mRCC is poorly defined. Aims: To study the effect of ASIs on the outcome sunitinib tx for mRCC. Methods: We performed a retrospective study of an unselected cohort of pts with mRCC, who were treated with 50 mg of oral sunitinib in cycles of 4 weeks followed by 2 weeks of rest. Pts were divided into 2 groups: (1) ASIs users and (2) ASIs naive. The effect of ASIs use on objective response, time to progression (TTP) and overall survival (OS), was tested with adjustment of other known confounding risk factors using a chisquare test and partial likelihood test from cox model. Results: Between 2004-2010, 124 pts with mRCC were treated with sunitinib. There were 44 ASIs users (group 1) and 80 nonusers (group 2). With regard to sunitinib tx initiation time, 39 users started ASIs before, 3 within 1 month, and 2 after 5 months. The groups were balanced regarding the following known clinical prognostic factors: past nephrectomy, RCC histology, time from diagnosis to tx, ≥ 2 metastatic sites, lung/liver/bone metastasis, ECOG performance status, Hb level, corrected ca > 10 mg/dL, platelets count, prior cytokines/ targeted tx, sunitinib induced HTN, % pts that had dose reduction/tx interruption, and mean dose/cycle. Objective response in group 1 vs 2 was partial response (PR) 48% vs 38% (p=0.24), stable disease (SD) 38% both, and progressive disease (PD) 14% vs 24% (p=0.19). Median TTP was 12 vs 6 ms (HR 0.635 in ASIs users, p=0.034). Median OS was 25 vs 22 ms (HR 0.756, p=0.31). Conclusions: ASIs may improve the outcome of pts with mRCC that are treated with sunitinib. This should be investigated prospectively, and if validated, applied in clinical practice and clinical trials.
Address
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lettsomian Lectures ON JAUNDICE: WITH SPECIAL REFERENCE TO TYPES OCCURRING DURING THE WAR
Authors: W. H. Willcox
Journal: BMJ (1919)

SPECIFIC FEVERS AND INFECTIONS.RELAPSING FEVER (CHARTS 1-6).RELAPSING fever is due to blood infection by the spirochaete of.Obermeier, the mode of transmission, as shown by Macide, being tlhrough the louse, The disease is endemic in Mesopotamia, Persia, and Egypt, and, in-Relapsing fever (Britib).A, Blood negative to spi B, blood positive.c, SElvarsan 0 3 gram.Note tibe period < from the fifteenth to the twenty-second day.oonsequence of unavoidable association with the nativ who were employed in labour corps, etc., infection spret to some extent to our troops, and I have had exception opportunities of studying -the disease not only in Brtish, but.als in Indians, Arabs, Persians, and Egyptians.The onset of the disease is sudden and acute.Jaundice occuirs quite early, ofteni on the first or second day; it is usually quite marked and in some cases deep.Captain M. A. Nicholson, I.M.S., from a careful examination of 241 cases at the Isolation Hospital, Baghdad, most of wlhich I saw with him, found jauindice present in 64 per cent.This figure is interesting because in a reoent paper"O on spiro- chaetosis icterohaemorrhagica by Stokes, Rlyle, and S Tytler, the estimate of 60 per cent. is given for the ,oecurrence rate of jaundice, which is in Tery close agreement with our figures for relapsing fever in Mesopotamia.Enlargement of the liver was observed in 41 per cent.4 the cases.Jaundice in relapsing fever is due, no doubt, t m.c 26 1227129 .3031I"J 2 3 4 _1 7 8 9 1 I f 12 1 3 rz TTp.t EL MJL MLE ILE O EL SU 107.-A Ciit C R jjELMM2"I [I ~~~~~~A IC".I03.
Electroencephalography
Authors: John A. Abbott
Journal: New England Journal of Medicine (1955)

The successive anatomic structures (1, 2, 3 and 4 below) traversed or penetrated by the impulses of the neurons that constitute the nonspecific afferent system are as follows:(1) Reticular formation and periaqueductal gray matter of brain stem.(2) Subthalamus and hypothalamus adjacent to third ventricle.(3) Thalamus.(4) Cerebral cortex.There is also (3′) a parallel extrathalamic avenue describable as follows:(2) Subthalamus and hypothalamus adjacent to third ventricle.(3′) Internal capsule.(4) Cerebral cortex.The course that these impulses take through (3) the thalamus and thence into (4) the cerebral cortex is especially controversial, and its description may . . .